Aigenpulse strengthens management team with appointment of Chief Product Officer

Oxford, UK, 08 October 2018: Aigenpulse Ltd., (Aigenpulse), a company at the forefront of employing data technologies and advanced machine learning to accelerate drug discovery, today announced the appointment of Dr Satnam Surae as Chief Product Officer. The appointment continues the rapid expansion of the company, which has grown four-fold in the last year and is the first in a series of senior appointments.

Dr Surae was the first employee at Aigenpulse when he joined in October 2016, and most recently held the role of Lead Computational Biologist. He has extensive experience in computational biology, previously working at Whitehat Analytics and INVISTA. Dr Surae gained his BSc in Biochemistry at the University of York, where he continued for his MRes in Computational Biology, during which time he also studied at the University of California San Diego in the laboratory of Prof. Phil Bourne. Dr Surae holds a PhD in Computational Structural Biology from University College Dublin where he worked in the Diabetes Complications Research Centre at the Conway Institute. 

The appointment is part of Aigenpulse’s strategy for growth in the biotech sector, specifically in response to customer recognition of the value created. The company’s dynamic software platform has been developed as an enterprise system to accelerate drug discovery, enabling precise data-driven decisions to be made with confidence. The data management system provides deep insight into operations and research activities, allowing improved traceability, auditability and visibility of progress within the drug discovery and development pipeline. This ensures that the commercially most attractive candidates are identified and pursued, ultimately increasing the efficiency at which new and improved drugs reach patients.

Tobias Kloepper, Chief Executive Officer at Aigenpulse, said: “Satnam’s experience has been a great asset to Aigenpulse to date, and in his new role he will support our sustained growth rate, as well as delivering our platform development targets. His appointment is an essential part of the steps we are taking to respond to customer needs, and ultimately in our mission to help make better drugs available to more people worldwide.”


About Aigenpulse:

Aigenpulse has developed a state of the art, dynamic software platform focussed on accelerating drug discovery by putting advanced data technologies and artificial intelligence at the heart of any R&D strategy. Researchers use the platform to structure, share and analyse their research data. Increasing data visibility and supporting data driven decision making. We enable forward-thinking biotechnology companies to generate and identify best in class drug candidates by facilitating the use of AI on their data. This ensures that drug discovery becomes more successful and affordable.  This means letting scientists focus on enhancing their experience & intuition with robust data-driven decision making, improving research outcomes across drug discovery. Bringing advanced data technologies to biotherapeutics R&D, the Aigenpulse platform is proving to be an invaluable asset by maximising the information gleaned from our customers’ data. Our mission is to combine machine learning and human expertise to facilitate the efficient creation of better drugs; making them available to more people.

Aigenpulse was founded in 2016 and has built a team of expert bioinformaticians, software engineers and project managers. The company is headquartered in Oxford, UK.

Media Contact Information: 


Aigenpulse contact:

Wendy Tindsley, Senior Business Development Manager

T: +44 (0) 7807 054617

Press contact:

Lorna Cuddon, Zyme Communications

T: +44 (0) 7811 996942


To opt-out from receiving press releases from Zyme Communications please email To view our privacy policy, please click here.